Default company panoramic image

USBiomarkers, Inc

Mature platform technology for diagnostic, predictive, and prognostic tests in blood. Blood-based companion diagnostics and monitoring.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Buffalo Grove, IL, USA
  • Currency USD
  • Founded February 2010
  • Employees 3
  • Website

Company Summary

USB develops and intends to market biomarkers and blood-based diagnostic (Dx) tests for cancer and neurodegenerative diseases (e.g. multiple sclerosis). The Dx market grows due to aging populations, and healthcare costs. Matching of drugs to patients (companion Dx) and patient monitoring (personalized medicine) require tests. Customers are individuals, pharma and molecular Dx companies, and medical groups.


  • Default avatar
    Victor Levenson
    President, CSO and interim CEO

    Dr. Levenson, MD (2nd Moscow State Medical School, 1981), and PhD (Molecular and Cellular Biology, Institute of Molecular Biology, Moscow, USSR, 1985) held faculty positions, received multiple awards from national foundations and NIH, published over 45 peer-reviewed articles, reviews. He acts as the interim CEO. His experience with project design for test/biomarker development is instrumental for USB success.

  • Default avatar
    Anatoliy Melnikov

    Dr. Melnikov, PhD (Genetic Engineering, Puschino, USSR, 1983) is a biochemist and enzymologist, who co-developed the MethDet technology for routine clinical analysis. He was a Sr. Group Leader at Integrated Genomics, Inc, a biotechnology company before joining with Dr. Levenson. He authored over 30 peer-reviewed publications and continues development of the assay to make it faster, cheaper, more accurate, and easier to perform.

  • Default avatar
    Sergei Bavykin

    Dr. Bavykin, MD (1975), PhD, and DSc (1980 and 1992) held faculty positions and authored more than 40 peer-reviewed papers, 7 patents and more than thirty software programs. He is an expert in microarray technology, bioassay development, and bioinformatics. He is responsible for bioinformatics analysis of data for high-resolution genome-wide development of tests/biomarkers.


  • Default avatar
    Brian Cyr
    Default avatar
    Brad Filmanowitz